Open Access
Research Article

Table 3

Relative sensitivity, specificity, PPV, and NPV by testing 82 positive and 272 negative samples for anti-toxoplasma IgG.a

Immunoassay and classification of equivocal result Sensitivityb (%) [95% CI] Specificityb (%) [95% CI] PPVc (%) NPVc (%)
Elecsys/Cobas 8000
 Positive 100 [100–100] 85.7 [82.0–89.3] 76.1 100
 Negative 73.2 [68.7–77.8] 99.3 [98.4–100] 97.8 89.0
Architect/i2000
 Positive 43.9 [38.7–49.1] 100 [100–100] 100 79.6
Platelia/Evolis
 Positive 36.6 [31.6–41.6] 100 [100–100] 100 77.6
 Negative 32.9 [28.0–37.8] 100 [100–100] 100 76.6
Access II/Access
 Positive 32.9 [28.0–37.8] 99.3 [28.4–100] 95.3 76.5
 Negative 13.4 [9.7–17.0] 99.6 [99–100] 94.3 71.6
TGS TA/IDS-iSYS
 Positive/Negative 46.3 [41.1–51.5] 96.7 [94.8–98.6] 86.4 79.8
Vidas II/Mini Vidas
 Positive 37.8 [32.7–42.9] 100 [100–100] 100 77.9
 Negative 12.2 [8.8–15.6] 100 [100–100] 100 71.4
Liaison II/Liaison XL
 Positive 13.4 [9.7–17.0] 100 [100–100] 100 71.7
 Negative 11.0 [7.7–14.2] 100 [100–100] 100 71.1

PPV, positive predictive value; NPV, negative predictive value.

a

The criteria were determined with the high and low cut-off values specified by the manufacturers. The confirmatory test was the Toxo II IgG Western blot (LDBio).

b

Performance values were calculated using the Toxo II IgG test Western blot as the reference test.

c

PPVs and NPVs were calculated using an estimated seroprevalence in France (31.3%).

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.